NUDT16: A Potential Drug Target and Biomarker for SnRNA-Decapping Enzyme

Target Name: NUDT16

NCBI ID: G131870

NUDT16: A Potential Drug Target and Biomarker for SnRNA-Decapping Enzyme

NUDT16 is a non-coding RNA-protein hyprophonegmental hybridization enzyme that is expressed in various tissues of the body. It is a key player in the process of snRNA-decapping, which is the breaking down of pre-mRNA by removing the 7-slice RNA cap. NUDT16 is a crucial enzyme in this process and is involved in the regulation of gene expression, thereby influencing cellular processes such as cell growth, differentiation, and apoptosis.

Recent studies have identified NUDT16 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases. NUDT16 has been shown to be involved in the regulation of various cellular processes, including cell cycle progression, apoptosis, and inflammation. Its involvement in these processes makes it an attractive target for therapeutic intervention.

One of the potential benefits of targeting NUDT16 is its potential to inhibit the activity of gene transcriptases that are involved in cancer progression. NUDT16 is known to be involved in the regulation of gene expression and has been shown to play a role in the regulation of cancer cell proliferation. By inhibiting the activity of NUDT16, researchers may be able to reduce the growth and spread of cancer cells.

Another potential benefit of targeting NUDT16 is its potential to treat neurodegenerative diseases. NUDT16 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is crucial for the function of the nervous system. In neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, the regulation of neurotransmitter synthesis and release is disrupted, leading to the progressive loss of brain cells and the development of symptoms. By targeting NUDT16, researchers may be able to treat neurodegenerative diseases by restoring the normal function of the nervous system.

Targeting NUDT16 may also be a potential approach to treating systemic inflammatory diseases. NUDT16 has been shown to be involved in the regulation of inflammation and has been shown to play a role in the development of various inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. By targeting NUDT16, researchers may be able to treat systemic inflammatory diseases by inhibiting its activity and reducing inflammation.

In conclusion, NUDT16 is a non-coding RNA-protein hybridization enzyme that is involved in the regulation of various cellular processes, including cell cycle progression, apoptosis, and inflammation. Its potential as a drug target and biomarker makes it an attractive target for therapeutic intervention in a variety of diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases. Further research is needed to fully understand the role of NUDT16 in these diseases and to develop effective treatments.

Protein Name: Nudix Hydrolase 16

Functions: RNA-binding and decapping enzyme that catalyzes the cleavage of the cap structure of snoRNAs and mRNAs in a metal-dependent manner. Part of the U8 snoRNP complex that is required for the accumulation of mature 5.8S and 28S rRNA. Has diphosphatase activity and removes m7G and/or m227G caps from U8 snoRNA and leaves a 5'monophosphate on the RNA. Catalyzes also the cleavage of the cap structure on mRNAs. Does not hydrolyze cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG). Also hydrolysis m7G- and m227G U3-capped RNAs but with less efficiencies. Has broad substrate specificity with manganese or cobalt as cofactor and can act on various RNA species. Binds to the U8 snoRNA; metal is not required for RNA-binding. May play a role in the regulation of snoRNAs and mRNAs degradation. Acts also as a phosphatase; hydrolyzes the non-canonical purine nucleotides inosine diphosphate (IDP) and deoxyinosine diphosphate (dITP) as well as guanosine diphosphate (GDP), deoxyguanosine diphosphate (dGDP), xanthine diphosphate (XDP), inosine triphosphate (ITP) and deoxyinosine triphosphate (ITP) to their respective monophosphate derivatives and does not distinguish between the deoxy- and ribose forms (PubMed:20385596, PubMed:26121039). The order of activity with different substrates is IDP > dIDP >> GDP = dGDP > XDP = ITP = dITP (PubMed:20385596). Binds strongly to GTP, ITP and XTP. Participates in the hydrolysis of dIDP/IDP and probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions (PubMed:20385596). Exhibits decapping activity towards NAD-capped RNAs and FAD-capped RNAs (PubMed:32432673). Exhibits decapping activity towards dpCoA-capped RNAs in vitro (By similarity)

More Common Targets